The emotional bond between pets and their owners is fundamental to their well-being. Vetoquinol therefore strives to develop products that are not only effective, but also easy to administer, with special emphasis on the palatability of its tablets for cats and dogs.
For their favourite pets, cat and dog owners expect a level of healthcare equivalent to that which humans receive.
For veterinarians and pet owners alike, it is essential that the products be user-friendly, easy to handle and administer, and that they cover the full spectrum of pet diseases.
Vetoquinol therefore provides a wide and comprehensive range of products: against infections, pain and inflammation, for behavioural issues, urinary incontinence, liver disease, heart and kidney failure, and against external and internal parasites, as well as pet care and hygiene products.
Minimising pet pain: an ethical issue
Animal welfare is gaining increasing importance; the treatment of pain has thus become both an ethical issue and a major need in modern society.
To address this need, Vetoquinol has developed a comprehensive range of products for pain relief and prevention in cats and dogs.
Items in this range include non-steroidal anti-inflammatories (NSAIDs) such as Cimalgex®, Tolfedine®, and dietary supplements such as Flexadin® and Caniviton® for the management of osteoarthritis.
Heart and renal failure are among the most common chronic conditions affecting dogs and older cats, respectively. While 10% of dogs suffer from heart disease, the risk is higher in certain breeds and lines. These conditions affect the metabolism and behaviour of dogs, impairing their quality of life and reducing their life expectancy.
As a pioneer in the field, Vetoquinol develops innovative therapeutic solutions and is the first veterinary company to offer such a wide range of products.
Vetoquinol has long invested in cardiology, lending strong support to opinion leaders in their research. In 2015, Vetoquinol launched an innovative new drug, UpCard®, a genuine breakthrough in the treatment of congestive heart failure.
Warning: these web pages are intended for English speaking users, excluding users based on French territory. To access information for French residents, please visit the dedicated website: www.vetoquinol.fr.
These pages are general information pages of the Vetoquinol Group. Products ranges are tailored to accommodate local demand and regulatory requirements which may change from one country to the next. For further information about the products in accordance with applicable national regulations, please refer to the Vetoquinol website for your country. The information provided depends on national registrations. The technical information is only accessible to authorised persons.